Tvardi Therapeutics (NASDAQ:TVRD) Price Target Cut to $15.00 by Analysts at BTIG Research

Tvardi Therapeutics (NASDAQ:TVRD) had its price objective decreased by BTIG Research from $55.00 to $15.00 in a report released on Monday,Benzinga reports. BTIG Research currently has a buy rating on the stock.

Other research analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Saturday, September 27th. Barclays began coverage on Tvardi Therapeutics in a research note on Monday. They issued an “overweight” rating and a $61.00 price objective on the stock. Cantor Fitzgerald downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday. Piper Sandler downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday. Finally, Raymond James Financial began coverage on Tvardi Therapeutics in a research report on Monday, July 14th. They issued an “outperform” rating and a $62.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Tvardi Therapeutics currently has a consensus rating of “Hold” and an average target price of $46.17.

Tvardi Therapeutics Trading Down 83.9%

Shares of TVRD stock opened at $6.69 on Monday. The firm has a 50 day moving average of $31.63. Tvardi Therapeutics has a twelve month low of $5.65 and a twelve month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $2,617,000. Marshall Wace LLP bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $583,000. Bank of America Corp DE bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $399,000. New York State Common Retirement Fund bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $92,000. Finally, Headlands Technologies LLC bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $80,000. 44.66% of the stock is owned by institutional investors.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.